MetaCap

Faeth Therapeutics (FTH) vs NervGen Pharma (NGEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Faeth Therapeutics (FTH) has outperformed NervGen Pharma (NGEN) over the past year, losing 9.6% versus a loss of 35.0%. Over five years, NGEN leads with a -9.6% price change compared with -95.0% for FTH. Faeth Therapeutics is the larger company by market cap ($203.7 million vs $198.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FTH-9.64%NGEN-35.04%
+380%+153%-74%
Nov 21, 20251 yearNov 20, 2026
FTH-95.34%NGEN-16.85%
+178%+34%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FTH versus NGEN key metrics
MetricFTHNGEN
Share price$7.88$1.85
Market cap$203.65M$198.55M
1-day change-9.32%-3.91%
YTD return-26.15%-67.05%
1-year return-9.64%-35.04%
5-year return-94.96%-9.56%
EPS (TTM)$-22.50$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-21.09M—
52-week high$42.14$6.30
52-week low$7.45$1.28
Distance from 52-week high-81.30%-70.71%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+612.56%+442.01%
Average volume500.25K621.66K
Shares outstanding25.84M107.62M
Employees299
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FTH has outperformed NGEN by 25.4 percentage points over the past year.

About Faeth Therapeutics

FTH stock →

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

About NervGen Pharma

NGEN stock →

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

FTH vs NGEN FAQ

Which is bigger, Faeth Therapeutics or NervGen Pharma?

Faeth Therapeutics (FTH) is larger, with a market capitalization of $203.65M compared with $198.55M for NervGen Pharma (NGEN).

Which stock has performed better over the past year, FTH or NGEN?

FTH returned -9.64% over the past 12 months, compared with -35.04% for NGEN (price return, excluding dividends). Past performance does not predict future results.

Are Faeth Therapeutics and NervGen Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons